# A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of Trebananib (AMG 386 ) in Adult Japanese Participants With Advanced Solid Tumors

> **NCT02525536** · PHASE1 · COMPLETED · sponsor: **Takeda** · enrollment: 18 (actual)

## Conditions studied

- Neoplasms, Advanced Solid

## Interventions

- **DRUG:** Trebananib 3 mg/kg
- **DRUG:** Trebananib 10 mg/kg
- **DRUG:** Trebananib 30 mg/kg

## Key facts

- **NCT ID:** NCT02525536
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2014-05
- **Final completion:** 2014-05
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2015-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02525536

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02525536, "A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of Trebananib (AMG 386 ) in Adult Japanese Participants With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT02525536. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*